Petros Efthimiou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Petros Efthimiou has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Apostolos Kontzias
1 shared publicationCarla M Ward
1 shared publicationL Bielory
Department of Medicine, Division of Allergy, Immunology, and Rheumatology, New Jersey Medical School, UMDNJ, Newark, NJ 07101, USA
1 shared publicationL J Kagen
Department of Medicine, Hospital for Special Surgery, New York, USA; New York Presbyterian Hospital, Weill Medical College of Cornell University, New York
1 shared publicationNeeta S Ogden
1 shared publicationP K Paik
Department of Medicine, Weill Medical College of Cornell University, NY, NY 10021, USA
1 shared publication
Latest Publications
- 1 June 2007
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 3 (6) , 328-335
Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?
Adult-onset Still's disease is a rare systemic inflammatory disease of unknown etiology, characterized by daily high, spiking fevers, evanescent rash, and arthritis. There is no single diagnostic test for adult-onset Still's disease; rather, the diagnosis is based on clinical criteria and necessitates the exclusion of infectious, neoplastic, and other 'autoimmune' diseases. Proinflammatory cytokines such as interleukin (IL)-1, IL-6, and IL-18, interferon-gamma, tumor necrosis factor, and macrophage colony-stimulating factor are elevated in patients with adult-onset Still's disease and are thought to have a major role in the pathogenesis of the disease. Treatment consists of nonsteroidal anti-inflammatory drugs, corticosteroids, immunosuppressants (methotrexate, gold, azathioprine, leflunomide, cyclosporin, and cyclophosphamide), intravenous immunoglobulin, and cytokine (tumor necrosis factor, IL-1 and IL-6) inhibitors. Recent advances in basic immunology have enhanced our ability to hinder the pathogenic mechanisms associated with adult-onset Still's disease and have led to a paradigm shift where targeted treatments have an increasingly important role.
- 1 June 2007
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 3 (6) , 328-335
Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?
Adult-onset Still's disease is a rare systemic inflammatory disease of unknown etiology, characterized by daily high, spiking fevers, evanescent rash, and arthritis. There is no single diagnostic test for adult-onset Still's disease; rather, the diagnosis is based on clinical criteria and necessitates the exclusion of infectious, neoplastic, and other 'autoimmune' diseases. Proinflammatory cytokines such as interleukin (IL)-1, IL-6, and IL-18, interferon-gamma, tumor necrosis factor, and macrophage colony-stimulating factor are elevated in patients with adult-onset Still's disease and are thought to have a major role in the pathogenesis of the disease. Treatment consists of nonsteroidal anti-inflammatory drugs, corticosteroids, immunosuppressants (methotrexate, gold, azathioprine, leflunomide, cyclosporin, and cyclophosphamide), intravenous immunoglobulin, and cytokine (tumor necrosis factor, IL-1 and IL-6) inhibitors. Recent advances in basic immunology have enhanced our ability to hinder the pathogenic mechanisms associated with adult-onset Still's disease and have led to a paradigm shift where targeted treatments have an increasingly important role.
- 1 February 2007
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (2) , 276
QuantiFERON TB Gold Test: the new standard for screening of latent tuberculosis in patients with rheumatoid arthritis?
Although screening policies vary considerably between countries, it is generally recommended that all patients with rheumatoid arthritis should undergo screening for Mycobacterium tuberculosis latent infection before the initiation of treatment with biological agents, especially tumour necrosis factor (TNF)α inhibitors. …
- 1 February 2007
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (2) , 276
QuantiFERON TB Gold Test: the new standard for screening of latent tuberculosis in patients with rheumatoid arthritis?
Although screening policies vary considerably between countries, it is generally recommended that all patients with rheumatoid arthritis should undergo screening for Mycobacterium tuberculosis latent infection before the initiation of treatment with biological agents, especially tumour necrosis factor (TNF)α inhibitors. …
- 1 December 2006
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 36 (3) , 168-172
Tumor Necrosis Factor-α in Inflammatory Myopathies: Pathophysiology and Therapeutic Implications
- 1 December 2006
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 36 (3) , 168-172
Tumor Necrosis Factor-α in Inflammatory Myopathies: Pathophysiology and Therapeutic Implications
- 1 December 2006
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 36 (3) , 144-152
Pathogenesis and Management of Adult-Onset Still’s Disease
- 1 December 2006
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 36 (3) , 144-152
Pathogenesis and Management of Adult-Onset Still’s Disease
- 1 September 2006
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (9) , 1233-1236
Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients
Objective: To understand the use of tumour necrosis factor (TNF)α inhibitors in refractory dermatomyositis and polymyositis in an academic centre. Methods: A retrospective study of eight patients with dermatomyositis or polymyositis refractory to corticosteroids and immunosuppressives who were treated with TNF inhibitors between 1998 and 2004. Results: 8 patients with dermatomyositis or polymyositis who were treated with TNF inhibitors as adjunct treatment were identified. The mean (SD) duration of disease before initiation of TNF inhibitors was 8.5 (4.4) years. The patients failed to respond to treatment with corticosteroids (oral and intravenous); intravenous immunoglobulin and immunosuppressants (methotrexate, azathioprine, mucophenolate mofetil and leflunomide); 4.5 (1.4) immunosuppressants had been used before TNF treatment. Six patients were treated with etanercept alone, one with infliximab and one sequentially with both agents. Of the eight patients, six showed a favourable response with improved motor strength and decreased fatigue after 15.2 (6.5) months. Two of the patients did not respond after 4 (1.4) months and TNF inhibitors were discontinued. Responders showed a 54.4% (27.7%) decrease in serum concentration of creatine kinase, which was grossly abnormal (4463.5 (4036.4) U/l). Non-responders had similar reductions in creatine kinase concentration (56.1% (20.4%)), but their pre-treatment concentrations were in the normal range (118.5 (19.1) U/l). Conclusion: Anti-TNF agents may be useful in some patients with refractory dermatomyositis or polymyositis.
- 1 September 2006
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (9) , 1233-1236
Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients
Objective: To understand the use of tumour necrosis factor (TNF)α inhibitors in refractory dermatomyositis and polymyositis in an academic centre. Methods: A retrospective study of eight patients with dermatomyositis or polymyositis refractory to corticosteroids and immunosuppressives who were treated with TNF inhibitors between 1998 and 2004. Results: 8 patients with dermatomyositis or polymyositis who were treated with TNF inhibitors as adjunct treatment were identified. The mean (SD) duration of disease before initiation of TNF inhibitors was 8.5 (4.4) years. The patients failed to respond to treatment with corticosteroids (oral and intravenous); intravenous immunoglobulin and immunosuppressants (methotrexate, azathioprine, mucophenolate mofetil and leflunomide); 4.5 (1.4) immunosuppressants had been used before TNF treatment. Six patients were treated with etanercept alone, one with infliximab and one sequentially with both agents. Of the eight patients, six showed a favourable response with improved motor strength and decreased fatigue after 15.2 (6.5) months. Two of the patients did not respond after 4 (1.4) months and TNF inhibitors were discontinued. Responders showed a 54.4% (27.7%) decrease in serum concentration of creatine kinase, which was grossly abnormal (4463.5 (4036.4) U/l). Non-responders had similar reductions in creatine kinase concentration (56.1% (20.4%)), but their pre-treatment concentrations were in the normal range (118.5 (19.1) U/l). Conclusion: Anti-TNF agents may be useful in some patients with refractory dermatomyositis or polymyositis.
- 1 May 2006
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (5) , 564-572
Diagnosis and management of adult onset Still's disease
Background: Adult onset Still’s disease (AOSD) is a rare systemic inflammatory disorder of unknown aetiology that is responsible for a significant proportion of cases of fever of unknown origin and can also have serious musculoskeletal sequelae. Objective: To assess and synthesise the evidence for optimal diagnosis and management of AOSD. Methods: The key terms, adult onset Still’s disease, AOSD, adult Still’s disease, ASD, Still’s disease were used to search Medline (1966–2005) and PubMed (1966–2005) for all available articles in the English language. Clinically relevant articles were subsequently selected. Bibliographies, textbooks, and websites of recent rheumatology conferences were also assessed. Results: Data on diagnosis and treatment of AOSD are limited in the medical literature and consist mainly of case reports, small series, and modest scale retrospective studies. Diagnosis is clinical and requires exclusion of infectious, neoplastic, and other autoimmune diseases. Laboratory tests are non-specific and reflect heightened immunological activity. Treatment comprises non-steroidal anti-inflammatory drugs, corticosteroids, immunosuppressive drugs (methotrexate, leflunomide, gold, azathioprine, ciclosporin A, cyclophosphamide), and intravenous gammaglobulin. The recent successful application of biological agents (anti-tumour necrosis factor, anti-interleukin (IL)1, anti-IL6), often in combination with traditional immunosuppressive drugs, has been very promising. Conclusions: AOSD often poses a diagnostic and therapeutic challenge and clinical guidelines are lacking. The emergence of validated diagnostic criteria, discovery of better serological markers, and the application of new biological agents may all provide the clinician with significant tools for the diagnosis and management of this complex systemic disorder.
- 1 May 2006
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (5) , 564-572
Diagnosis and management of adult onset Still's disease
Background: Adult onset Still’s disease (AOSD) is a rare systemic inflammatory disorder of unknown aetiology that is responsible for a significant proportion of cases of fever of unknown origin and can also have serious musculoskeletal sequelae. Objective: To assess and synthesise the evidence for optimal diagnosis and management of AOSD. Methods: The key terms, adult onset Still’s disease, AOSD, adult Still’s disease, ASD, Still’s disease were used to search Medline (1966–2005) and PubMed (1966–2005) for all available articles in the English language. Clinically relevant articles were subsequently selected. Bibliographies, textbooks, and websites of recent rheumatology conferences were also assessed. Results: Data on diagnosis and treatment of AOSD are limited in the medical literature and consist mainly of case reports, small series, and modest scale retrospective studies. Diagnosis is clinical and requires exclusion of infectious, neoplastic, and other autoimmune diseases. Laboratory tests are non-specific and reflect heightened immunological activity. Treatment comprises non-steroidal anti-inflammatory drugs, corticosteroids, immunosuppressive drugs (methotrexate, leflunomide, gold, azathioprine, ciclosporin A, cyclophosphamide), and intravenous gammaglobulin. The recent successful application of biological agents (anti-tumour necrosis factor, anti-interleukin (IL)1, anti-IL6), often in combination with traditional immunosuppressive drugs, has been very promising. Conclusions: AOSD often poses a diagnostic and therapeutic challenge and clinical guidelines are lacking. The emergence of validated diagnostic criteria, discovery of better serological markers, and the application of new biological agents may all provide the clinician with significant tools for the diagnosis and management of this complex systemic disorder.